CD4 and pulmonary fibrosis: Sirolimus has been used therapeutically in CD4+ T cell–mediated fibrotic states, including idiopathic pulmonary fibrosis and renal interstitial fibrosis (18–20), making it a logical choice for testing as a potential therapeutic in LTS.